Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting [...]
04/2014
Journal Article
Authors:
Karantalis, V.;
DiFede, D.;
Gerstenblith, G.;
Pham, S.;
Symes, J.;
Zambrano, J.;
Fishman, J.;
Pattany, P.;
McNiece, I.;
Conte, J.;
, ;
Mendizabal, A.;
Karas, T.;
Byrnes, J.;
Lowery, M.;
Heldman, A.;
J, H.
Secondary:
Circ Res
Volume:
114
Pagination:
1302-1310
URL:
http://www.ncbi.nlm.nih.gov/pubmed/24565698
Keywords:
coronary artery bypass; mesenchymal stromal cells; stem cell
Abstract:
{RATIONALE: Although accumulating data support the efficacy of intramyocardial cell-based therapy to improve left ventricular (LV) function in patients with chronic ischemic cardiomyopathy undergoing CABG, the underlying mechanism and impact of cell injection site remain controversial. Mesenchymal stem cells (MSCs) improve LV structure and function through several effects including reducing fibrosis, neoangiogenesis, and neomyogenesis. OBJECTIVE: To test the hypothesis that the impact on cardiac structure and function after intramyocardial injections of autologous MSCs results from a concordance of prorecovery phenotypic effects. METHODS AND RESULTS: Six patients were injected with autologous MSCs into akinetic/hypokinetic myocardial territories not receiving bypass graft for clinical reasons. MRI was used to measure scar, perfusion, wall thickness, and contractility at baseline, at 3, 6, and 18 months and to compare structural and functional recovery in regions that received MSC injections alone, revascularization alone, or neither. A composite score of MRI variables was used to assess concordance of antifibrotic effects, perfusion, and contraction at different regions. After 18 months, subjects receiving MSCs exhibited increased LV ejection fraction (+9.4 ± 1.7%
